---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000286"
form_type: "8-K"
ticker: "CABR"
cik: "0002020737"
company_name: "Caring Brands, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:44:32.801829+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Caring Brands enters exclusive global license for Emesyl nausea relief product

## Summary
- Licensed Emesyl OTC nausea product from Itonis; exclusive worldwide rights to manufacture, market, distribute.
- 8% royalty on net sales; potential to earn 7% of Itonis equity per $200k in sales.
- License may terminate if sales ≤$25k for four consecutive quarters after launch.
- Global nausea treatment market projected >$6.23B in 2025, per QY Research.
- CEO notes expansion of health/wellness portfolio; further updates expected on timelines.

## SEC filing metadata
- accession: 0001493152-26-000286
- form_type: 8-K
- ticker: CABR
- cik: 0002020737
- company_name: Caring Brands, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2020737/000149315226000286/0001493152-26-000286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2020737/000149315226000286/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000286
- JSON: https://secwatch.observer/filing/0001493152-26-000286.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000286.txt

## Key facts
- Material Agreements
  Caring Brands, Inc. entered into License Agreement with Itonis Pharmaceuticals (effective 2025-12-31).
  - Action: entry
  - Agreement: license
  - Counterparty: Itonis Pharmaceuticals
  - Effective: 2025-12-31
  source text: On December 31, 2025, Caring Brands, Inc., a Nevada corporation, (the “ Company ”), entered into a license agreement (the “ License Agreement ”) with Itonis Pharmaceuticals (“ Itonis ”), a Nevada corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2020737/000149315226000286/0001493152-26-000286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.